Original Paper| Volume 35, ISSUE 12, P1688-1692, November 1999

Decreased toxicity and increased efficacy of cancer chemotherapy using the pineal hormone melatonin in metastatic solid tumour patients with poor clinical status


      Melatonin (MLT) has been proven to counteract chemotherapy toxicity, by acting as an anti-oxidant agent, and to promote apoptosis of cancer cells, so enhancing chemotherapy cytotoxicity. The aim of this study was to evaluate the effects of concomitant MLT administration on toxicity and efficacy of several chemotherapeutic combinations in advanced cancer patients with poor clinical status. The study included 250 metastatic solid tumour patients (lung cancer, 104; breast cancer, 77; gastrointestinal tract neoplasms, 42; head and neck cancers, 27), who were randomised to receive MLT (20 mg/day orally every day) plus chemotherapy, or chemotherapy alone. Chemotherapy consisted of cisplatin (CDDP) plus etoposide or gemcitabine alone for lung cancer, doxorubicin alone, mitoxantrone alone or paclitaxel alone for breast cancer, 5-FU plus folinic acid for gastro-intestinal tumours and 5-FU plus CDDP for head and neck cancers. The 1-year survival rate and the objective tumour regression rate were significantly higher in patients concomitantly treated with MLT than in those who received chemotherapy (CT) alone (tumour response rate: 42/124 CT+MLT versus 19/126 CT only, P<0.001; 1-year survival: 63/124 CT+MLT versus 29/126 CT only, P<0.001). Moreover, the concomitant administration of MLT significantly reduced the frequency of thrombocytopenia, neurotoxicity, cardiotoxicity, stomatitis and asthenia. This study indicates that the pineal hormone MLT may enhance the efficacy of chemotherapy and reduce its toxicity, at least in advanced cancer patients of poor clinical status.


      To read this article in full you will need to make a payment

      Purchase one-time access:

      Academic & Personal: 24 hour online accessCorporate R&D Professionals: 24 hour online access
      One-time access price info
      • For academic or personal research use, select 'Academic and Personal'
      • For corporate R&D use, select 'Corporate R&D Professionals'


      Subscribe to European Journal of Cancer
      Already a print subscriber? Claim online access
      Already an online subscriber? Sign in
      Institutional Access: Sign in to ScienceDirect


        • Abo T
        • Kawate K
        • Itoh K
        • Kumagai K
        Studies on the bioperiodicity of the immune response. Circadian rhythms of human T, B and NK cell traffic in the peripheral blood.
        J. Immunol. 1981; 126: 1360-1366
        • Wood P.A
        • Hrushesky W.J.M
        Chronopharmacodynamics of hematopoietic growth factors and antitumor cytokines.
        in: Hrushesky W.J.M Circadian Cancer Therapy. CRC Press, Boca Raton1994: 185-207
        • Arendt J
        Clin. Endocrinol. 1998; 29: 205-229
        • Brzezinski A
        Melatonin in humans.
        N. Engl. J. Med. 1997; 336: 186-195
        • Cos S
        • Fernandez R
        • Güezmes A
        • Sanchez-Barcelo E.J
        Influence of melatonin on invasive and metastatic properties of MCF-7 human breast cancer cells.
        Cancer Res. 1998; 58: 4383-4390
        • Jankovic B.D
        Neuroimmunomodulation. From phenomenology to molecular evidence.
        Ann. NY Acad. Sci. 1994; 741: 1-38
        • Regelson W
        • Pierpaoli W
        Cancer Invest. 1987; 5: 379-385
        • Lissoni P
        • Viviani S
        • Bajetta E
        • et al.
        A clinical study of the pineal gland activity in oncologic patients.
        Cancer. 1986; 57: 837-842
        • Di Bella L
        • Rossi M.T
        • Scalera G
        Perspectives in pineal functions.
        Prog. Brain Res. 1979; 52: 475-477
        • Lissoni P
        • Barni S
        • Crispino S
        • Tancini G
        • Fraschini F
        Endocrine and immune effects of melatonin therapy in metastatic cancer patients.
        Eur. J. Cancer Clin. Oncol. 1989; 25: 789-795
        • Sze S.F
        • Ng T.B
        • Liu W.K
        Antiproliferative effect of pineal indoles on cultured tumor cell lines.
        J. Pineal Res. 1993; 14: 27-33
        • Lissoni P
        • Paolorossi F
        • Tancini G
        • et al.
        Is there a role for melatonin in the treatment of neoplastic cachexia?.
        Eur. J. Cancer. 1996; 32A: 1340-1343
        • Bartsch C
        • Bartsch H
        • Lippert T.H
        Rationales to consider the use of melatonin as a chrono-oncotherapeutic drug.
        In Vivo. 1995; 9: 305-310
        • Bartsch C
        • Bartsch H
        • Lippert T.H
        The pineal gland and cancer.
        Cancer J. 1992; 5: 194-199
        • Molis T.M
        • Spriggs L.L
        • Jupiter Y
        • Hill S.M
        Melatonin modulation of estrogen-regulated proteins, growth factors, and proto-oncogenes in human breast cancer.
        J. Pineal Res. 1995; 18: 93-103
        • Reiter R
        • Tang Lei
        • Garcia J.J
        • Munoz-Hoyos A
        Pharmacological actions of melatonin in oxygen radical pathophysiology.
        Life Sci. 1997; 60: 2255-2271
        • Lissoni P
        • Barni S
        • Tancini G
        • et al.
        A randomised study with subcutaneous low-dose interleukin-2 alone vs interleukin-2 plus the pineal neurohormone melatonin in advanced solid neoplasms other than renal cancer and melanoma.
        Br. J. Cancer. 1994; 69: 196-199
        • Reiter R
        • Carneiro R.C
        • Oh C.S
        Melatonin in relation to cellular antioxidative defense mechanisms.
        Horm. Metab. Res. 1997; 29: 363-372
        • Morishima I
        • Matsui H
        • Mukawa H
        • et al.
        Melatonin, a pineal hormone with antioxidant property, protects against adriamycin cardiomyopathy in rats.
        Life Sci. 1998; 63: 511-521
        • Lissoni P
        • Paolorossi F
        • Ardizzoia A
        • et al.
        A randomized study of chemotherapy with cisplatin plus etoposide versus chemoendocrine therapy with cisplatin, etoposide and the pineal hormone melatonin as a first-line treatment of advanced non-small cell lung cancer patients in a poor clinical state.
        J. Pineal Res. 1997; 23: 15-19
        • Lissoni P
        • Barni S
        • Paolorossi F
        • et al.
        Chemotherapy with 5-fluorouracil and folates versus chemoendocrinotherapy with 5-fluorouracil, folates and the pineal hormone melatonin in advanced gastrointestinal tract tumor patients of poor clinical status.
        Acta Gerontol. 1997; 47: 21-24
        • Maestroni G.J.M
        • Conti A
        • Lissoni P
        Colony-stimulating activity and hematopoietic rescue from cancer chemotherapy compounds are induced by melatonin via endogenous interleukin-4.
        Cancer Res. 1994; 54: 4740-4744
        • Lissoni P
        • Barni S
        • Brivio F
        • et al.
        Treatment of cancer-related thrombocytopenia by low-dose subcutaneous interleukin-2 plus the pineal hormone melatonin.
        J. Biol. Regul. Homeostat. Agents. 1995; 9: 52-54
        • Maestroni G.J.M
        The immunoneuroendocrine role of melatonin.
        J. Pineal Res. 1993; 14: 1-10
        • Lissoni P
        • Tancini G
        • Barni S
        • et al.
        Therapy of cancer chemotherapy-induced toxicity by the pineal hormone melatonin.
        Support Care Cancer. 1997; 5: 126-129
        • Mayo J.C
        • Sainz R.M
        • Uria H
        • et al.
        Inhibition of cell proliferation.
        J. Pineal. Res. 1998; 25: 12-18
        • Chinery R
        • Brockman J.A
        • Peeler M.O
        • et al.
        Antioxidants enhance the cytotoxicity of chemotherapeutic agents in colorectal cancer.
        Nature Med. 1997; 3: 1233-1238